NBCRNA Prep: High-Yield Pharmacology and Pathophysiology Topics for the Nurse Anesthesia Boards

Passing the NBCRNA exam demands more than memorizing drug lists. You need to connect pharmacology to physiology and make safe, fast decisions. This guide focuses on high-yield topics the boards like to test because they drive real intraoperative choices. For each point, you’ll see not just what to know, but why it matters and how it shows up in vignettes.

Exam patterns: what “high-yield” looks like

The boards favor scenarios where one physiological principle or drug property changes the entire plan. Expect questions that force you to choose between reasonable options by spotting a key detail (e.g., severe aortic stenosis, reactive airway, anticoagulation timing). Strong performers think in cause-and-effect: how this medication, disease, or monitor reading should change your next action.

Volatile and IV anesthetics: kinetics, MAC, and clinical traps

Minimum alveolar concentration (MAC) decreases with age, hypothermia, pregnancy, and acute alcohol. It increases with hyperthermia and chronic alcohol use. This matters because dosing based on “one MAC” isn’t one-size-fits-all. A 70-year-old needs less gas than a 20-year-old to avoid hypotension and delayed wake-up.

• MAC quick values: Sevoflurane ~2.0%, Desflurane ~6.0%, Isoflurane ~1.2%. Nitrous ~104% (not enough to anesthetize alone).
• Solubility drives speed: Low blood-gas solubility (desflurane) means fast on/off. High solubility (isoflurane) is slower. Kids go to sleep fast with gas because their high alveolar ventilation speeds uptake.
• Cardiorespiratory effects: All volatiles lower blood pressure via vasodilation; desflurane can increase heart rate and irritate airways, especially if turned up quickly. Sevoflurane is a bronchodilator and is gentler on the airway.
• Nitrous oxide: Diffuses into closed spaces (pneumothorax, bowel obstruction, middle ear) and can expand them. It also increases PONV risk. If the vignette features bowel surgery or recent eye surgery, avoid it.

IV induction agents differ in hemodynamics and organ effects. The boards test matching the agent to the physiology:

• Propofol: Hypotension from vasodilation and mild negative inotropy. Good for antiemesis and reducing airway reactivity. Avoid as sole agent in severe hypovolemia or cardiogenic shock.
• Etomidate: Hemodynamically stable but causes adrenal suppression. Safe for tenuous EF during induction, but avoid prolonged infusions and use caution in septic shock where cortisol response matters.
• Ketamine: Sympathomimetic (increases HR/BP), bronchodilates, preserves airway reflexes. Useful in hypovolemia or bronchospasm. Raises CMRO2/CBF/ICP; avoid in uncontrolled intracranial pathology.
• Barbiturates (thiopental): Reduce CMRO2/ICP but cause hypotension; less commonly used, but the neuro benefit is testable.

Dosing anchors: Propofol 1.5–2.5 mg/kg IV; Etomidate 0.2–0.3 mg/kg IV; Ketamine 1–2 mg/kg IV (4–6 mg/kg IM for pediatric induction).

Opioids, adjuncts, and PONV strategy

Boards love questions on opioid choice, timing, and respiratory risk.

• Mu agonists depress ventilation (reduced CO2 responsiveness), cause bradycardia, and can cause chest wall rigidity with rapid, high-dose fentanyl/remifentanil. The “why” is central mu-receptor effects on brainstem respiratory centers.
• Remifentanil has a context-insensitive half-time (~3–5 minutes) due to ester hydrolysis. Great for titration but expect postoperative hyperalgesia if not covered with longer-acting analgesics.
• Multimodal analgesia (acetaminophen, NSAIDs when appropriate, ketamine low-dose, dexmedetomidine) reduces opioid use and PONV risk by targeting different pain pathways.
• PONV risk factors: Female, nonsmoker, history of PONV/motion sickness, postoperative opioids. Treat with two to three classes: dexamethasone at induction, and a 5-HT3 antagonist before emergence; consider droperidol or scopolamine patch for high risk.

Neuromuscular blockers and reversal

Succinylcholine depolarizes the endplate and gives rapid onset. It temporarily raises serum potassium (~0.5 mEq/L), but in upregulated extrajunctional receptor states (burns, spinal cord injury, stroke, prolonged immobilization, muscular dystrophy) it can cause dangerous hyperkalemia. Avoid after 24–48 hours post-injury and for many months thereafter.

• Contraindications/precautions: Hyperkalemia, MH risk, pseudocholinesterase deficiency (prolonged paralysis), severe acidosis, neuromuscular disease.
• Nondepolarizers: Aminosteroids (rocuronium, vecuronium) and benzylisoquinoliniums (cisatracurium). Cisatracurium is organ-independent (Hofmann elimination), useful in renal/hepatic failure.
• Monitoring: Aim for a quantitative TOF ratio > 0.9 before extubation. Qualitative fade is not reliable. Deep block shows post-tetanic counts without TOF.
• Reversal:
  • Neostigmine 0.02–0.07 mg/kg with glycopyrrolate 0.01 mg/kg. Only when there is at least some recovery (e.g., ≥2 twitches).
  • Sugammadex binds rocuronium/vecuronium: 2 mg/kg for moderate block (TOF 2+), 4 mg/kg for deep block (PTC 1–2), 16 mg/kg for immediate reversal of RSI rocuronium. Caution in severe renal impairment. Advise backup contraception for 7 days after use due to steroid-binding interaction.

Local anesthetics and LAST

Amides (lidocaine, bupivacaine, ropivacaine) are hepatically metabolized; esters (chloroprocaine, tetracaine) are hydrolyzed by plasma cholinesterase. Toxicity shows up first as CNS symptoms (tinnitus, perioral numbness, seizures), then CV collapse. Bupivacaine is the most cardiotoxic due to tight sodium channel binding.

• Max doses: Lidocaine plain ~4.5 mg/kg (max ~300 mg), with epi ~7 mg/kg; Bupivacaine ~2.5–3 mg/kg; Ropivacaine ~3 mg/kg. The “why” is preventing plasma levels that saturate sodium channels in the heart and brain.
• LAST management: Airway and oxygen first to prevent acidosis (acidosis worsens toxicity), treat seizures with benzodiazepines, avoid large propofol doses if unstable. Lipid 20%: bolus 1.5 mL/kg, then infusion 0.25 mL/kg/min. If instability persists, repeat bolus and increase to 0.5 mL/kg/min. Continue for at least 10 minutes after stability; typical upper limit ~10 mL/kg over 30 minutes.

Autonomic drugs and hemodynamics

• Phenylephrine (α1) increases SVR, may reduce HR/CO. Best when you need afterload (e.g., aortic stenosis) or have tachycardia.
• Ephedrine indirect and direct agonist; increases HR and contractility. Tachyphylaxis occurs with catecholamine depletion; less effective in sepsis or after multiple doses.
• Norepinephrine α1 with some β1; first-line for septic shock because it raises MAP with less tachycardia than epinephrine and supports coronary perfusion.
• Vasopressin V1-mediated vasoconstriction; works in acidemia and catecholamine-refractory states; minimal effect on pulmonary vasculature at low doses.
• Labetalol (α and β blocker) controls hypertension with less reflex tachycardia; Esmolol short-acting β1 blocker useful for blunt tachycardic responses during stimulation.
• Vasodilators: Nitroglycerin (venodilator; good for preload reduction, coronary ischemia), Nitroprusside (arterial and venous; cyanide toxicity risk in high doses/renal failure).

Ventilation, oxygenation, and acid–base

Alveolar oxygen: PAO2 = FiO2 × (Patm − PH2O) − PaCO2/R. The gradient (A–a) = PAO2 − PaO2. A large A–a gradient means V/Q mismatch or shunt. Why it matters: Shunt will not correct fully with oxygen; V/Q mismatch improves with increased FiO2 and PEEP.

• Alveolar ventilation Va = (Vt − Vd) × RR. PaCO2 is inversely proportional to Va. Increasing RR lowers PaCO2 only if you reduce dead space or increase effective tidal volume.
• V/Q basics: Shunt (perfused, not ventilated) drops PaO2; dead space (ventilated, not perfused) raises PaCO2 and increases ETCO2–PaCO2 gradient.
• Bronchospasm/air-trapping: Prolong expiration (I:E 1:3–1:4), reduce rate, and deepen anesthesia. Auto-PEEP reduces venous return and can cause hypotension—disconnect briefly to relieve.
• Acid–base: Respiratory acidosis from hypoventilation raises K+; metabolic acidosis stimulates ventilation. Lactic acidosis suggests shock or hypoperfusion; treat the cause, not just the number.

Cardiovascular disease: anesthetic goals by lesion

• Aortic stenosis: Maintain preload and afterload, keep sinus rhythm, avoid tachycardia/hypotension. Phenylephrine is your friend; neuraxial sympathectomy can cause collapse—dose carefully or avoid if severe/critical.
• Mitral regurgitation: Faster HR and lower afterload reduce regurgitant fraction. Avoid bradycardia and high SVR.
• HOCM: Avoid tachycardia, inotropy, and vasodilation. Use phenylephrine; avoid ephedrine and inotropes that worsen LVOT obstruction.
• Ischemic heart disease: Supply–demand balance: maintain MAP for coronary perfusion, avoid tachycardia and anemia, treat pain promptly. Beta-block as needed for rate control.
• Heart failure: Optimize preload without overload, maintain afterload, avoid myocardial depressants. Consider etomidate for induction if EF is low.

Pulmonary disease and airway reactions

• Asthma/COPD: Pre-treat with bronchodilator, steroids if indicated. Choose sevoflurane, avoid desflurane during light anesthesia. For intraop bronchospasm, deepen anesthesia, give β2-agonist, consider epinephrine for severe cases, and avoid histamine-releasing drugs (morphine, atracurium).
• OSA: Higher risk of obstruction and desaturation post-op. Use multimodal analgesia, limit opioids, plan for awake extubation and extended monitoring.
• Laryngospasm: Remove stimulus, apply jaw thrust and CPAP with 100% O2, perform Larson’s maneuver, deepen with propofol, and if persistent, give succinylcholine (adults ~0.5–1 mg/kg IV; pediatrics 1 mg/kg IV or 4 mg/kg IM) with atropine in children.

Fluids, blood, and massive transfusion

Balanced crystalloids reduce hyperchloremic acidosis compared with normal saline. The “why”: high chloride lowers strong ion difference and drives metabolic acidosis, which decreases renal perfusion and coagulation function.

• Massive transfusion: Aim for balanced ratios (RBC:plasma:platelets ~1:1:1), warm everything, correct calcium (citrate binds Ca), and monitor fibrinogen. Watch for hyperkalemia with older blood. Consider calcium chloride (1 g) when giving large volumes.
• Transfusion triggers: Healthy adults often at Hb ≤7 g/dL; tailor to coronary disease, ongoing bleeding, and physiology.
• Compatibility: Some institutions avoid calcium-containing crystalloids through the same line as blood during rapid transfusion. Know your local policy; on exams, normal saline is the safe answer if you’re infusing blood rapidly.

Malignant hyperthermia: recognition and management

Triggers: Volatile anesthetics and succinylcholine. Early signs: rapid rise in ETCO2, tachycardia, rigidity, hyperkalemia, acidosis. Temperature may be late.

• Immediate actions: Stop triggers, call for help, 100% O2 with high flows, change circuit/CO2 absorbent if possible, notify surgeon to stop or abbreviate.
• Dantrolene: 2.5 mg/kg IV repeat until controlled (up to 10 mg/kg+). Continue 1 mg/kg every 4–6 hours or infusion ~0.25 mg/kg/hr for 24–48 hours due to recrudescence risk.
• Support: Cool to 38°C, treat acidosis (bicarbonate), treat hyperkalemia (calcium, insulin/glucose), maintain urine output, monitor CK, K, and coags in ICU.

Regional and neuraxial safety with anticoagulants

Neuraxial safety is timing. The “why”: you need normal coagulation at needle placement and catheter removal to prevent spinal hematoma.

• Aspirin/NSAIDs: Usually not a contraindication alone.
• Clopidogrel/prasugrel/ticagrelor: Hold ~5–7 days before neuraxial; resume after catheter removal per guidance.
• Warfarin: INR should be near normal (e.g., <1.4) before placement; remove catheter when INR is normalizing.
• LMWH: Prophylactic doses typically require ~12 hours before neuraxial; therapeutic doses ~24 hours. Respect timing for catheter removal and first postoperative dose.
• DOACs (apixaban, rivaroxaban, dabigatran): Many recommend holding ~72 hours before neuraxial; longer if renal impairment. Always confirm with the most current guidance.

Special populations: pregnancy, pediatrics, geriatrics, organ failure

• Pregnancy: MAC decreases by ~30%. Aortocaval compression reduces venous return—use left uterine displacement. Airway edema increases difficult intubation risk. Preeclampsia needs afterload control and neuraxial analgesia if platelets allow. Oxytocin boluses can cause hypotension and tachycardia—titrate.
• Pediatrics: High O2 consumption and low FRC mean quick desaturation; preoxygenate well. Laryngospasm is common—know the algorithm. Cuffed ETT sizing (approximate): (age/4) + 4. Leak test is more reliable than formulas.
• Geriatrics: Lower MAC, reduced physiologic reserve, higher sensitivity to opioids and sedatives. Dose-reduce and allow more time for circulation and effect.
• Renal failure: Avoid succinylcholine if hyperkalemic. Prefer cisatracurium for paralysis. Opioid metabolites (morphine, meperidine) accumulate—choose fentanyl or hydromorphone with care.
• Hepatic disease: Coagulopathy and low albumin change drug distribution and bleeding risk. Cisatracurium again is useful. Reduce doses of hepatically cleared sedatives; avoid excessive hypotension to protect liver perfusion.

Quick calculation and monitoring pearls

• SVR: SVR = (MAP − CVP) / CO × 80. A falling SVR with warm extremities suggests distributive shock; choose norepinephrine, not ephedrine.
• MAP estimate: MAP ≈ DBP + 1/3(Pulse Pressure). Coronary perfusion depends on MAP—protect it in CAD and severe AS.
• Pulse oximetry artifacts: Carboxyhemoglobin reads falsely high; methemoglobin pulls saturation toward ~85%. Treat methemoglobinemia with methylene blue if symptomatic and not G6PD-deficient.
• Capnography: Rising ETCO2 with stable ventilation suggests increased CO2 production or absorption (MH, sepsis, laparoscopy) or rebreathing (exhausted soda lime, faulty valve).
• Post-dural puncture headache: Worse sitting/standing, better supine; treat with fluids, caffeine, and if severe, epidural blood patch (~15–20 mL).

How to study: turn facts into decisions

• Link dose to physiology: Don’t memorize ketamine’s dose without the “why” (sympathomimetic that helps shock, raises ICP).
• Practice differentials: Rising ETCO2—list 3 causes and your first action for each. You’ll recall faster under pressure.
• Know “never” and “always” rules: Avoid succinylcholine in burns/denervation after 24–48 hours; stop triggers and give dantrolene for MH without waiting for a fever.
• Anchor dosing: Keep a short list of must-know doses (propofol, etomidate, ketamine, succinylcholine, neostigmine/glycopyrrolate, sugammadex, lipid rescue, dantrolene).
• Test yourself with scenarios: “Severe AS with hypotension after induction—what pressor and why?” “Asthmatic patient coughing on the tube—what’s first?”

The NBCRNA rewards applied understanding: pick the agent that fits the physiology, match the monitor change to its cause, and act safely when information is incomplete. If you can explain the “why” behind each choice—like you would to a colleague in the OR—you’re studying at the right level for the boards.

G S Sachin

I am a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. I hold a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research. With a strong academic foundation and practical knowledge, I am committed to providing accurate, easy-to-understand content to support pharmacy students and professionals. My aim is to make complex pharmaceutical concepts accessible and useful for real-world application.

Mail- Sachin@pharmacyfreak.com